Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

OraSure Technologies Faces Investor Pressure Amid Rejected Buyout Offer and Financial Challenges

OraSure Technologies Faces Investor Pressure Amid Rejected Buyout Offer and Financial Challenges

OraSure Technologies, a prominent infectious disease testmaker, is encountering increased pressure from investors following a rejected buyout offer and a significant drop in stock price over the past year. The company's situation has sparked discussions about potential changes to its board of directors and raised questions about its future direction.

NoahAI News9/10/2025
FDA Rejects Capricor's DMD Cell Therapy; Company Disputes Efficacy Interpretation

FDA Rejects Capricor's DMD Cell Therapy; Company Disputes Efficacy Interpretation

The U.S. Food and Drug Administration (FDA) has rejected Capricor Therapeutics' Duchenne muscular dystrophy (DMD) cell therapy, deramiocel, citing concerns over efficacy data interpretation and trial design. The company has responded, claiming the FDA misinterpreted key efficacy data that led to the rejection.

NoahAI News9/10/2025
Pulse Field Ablation Advances: New IDE Approval, $100M Funding, and Industry Expansion

Pulse Field Ablation Advances: New IDE Approval, $100M Funding, and Industry Expansion

Pulse Biosciences has secured Food and Drug Administration (FDA) approval to initiate a clinical study of its pulsed field ablation (PFA) system for treating atrial fibrillation during concomitant cardiac surgeries. The investigational device exemption (IDE) clears the way for the NANOCLAMP AF study, which will evaluate the company's nsPFA cardiac surgical device.

NoahAI News9/10/2025
UnitedHealth Anticipates Strong Medicare Advantage Performance for 2026

UnitedHealth Anticipates Strong Medicare Advantage Performance for 2026

UnitedHealth Group, the healthcare behemoth, has disclosed positive expectations for its Medicare Advantage (MA) plans in the upcoming year, signaling potential stability in the volatile MA market. This development comes amid industry-wide concerns over stricter quality metrics and margin pressures.

NoahAI News9/10/2025
UnitedHealth Group Anticipates Strong Performance in 2026 Medicare Advantage Star Ratings

UnitedHealth Group Anticipates Strong Performance in 2026 Medicare Advantage Star Ratings

UnitedHealth Group, the healthcare giant and largest provider of Medicare Advantage (MA) plans, has announced a positive outlook for its performance in the upcoming 2026 Medicare Advantage star ratings. The company's shares saw an uptick following the revelation, signaling investor confidence in UnitedHealth's continued strong position in the MA market.

NoahAI News9/10/2025
Inizio Shakes Up Leadership with New CEO Appointment

Inizio Shakes Up Leadership with New CEO Appointment

Inizio, a prominent player in the pharmaceutical services industry, has announced a significant change in its executive leadership. Ryan Quigley, previously the company's Chief Operating Officer, has been elevated to the role of Chief Executive Officer, effective Tuesday. This move marks a new chapter for the company, which was formed in 2022 through the merger of Ashfield and Huntsworth.

NoahAI News9/10/2025
Pfizer Veteran Suneet Varma Takes Helm at Innovative Regenerative Medicine Startup

Pfizer Veteran Suneet Varma Takes Helm at Innovative Regenerative Medicine Startup

In a significant move within the pharmaceutical industry, former Pfizer executive Suneet Varma has been appointed as the CEO of Intent Biologics, a newly formed regenerative medicine company. This development marks a new chapter in Varma's career and signals a promising advancement in the field of inflammation and immunology.

NoahAI News9/10/2025
Odyssey Therapeutics Secures $213M Series D Funding to Advance Clinical Portfolio

Odyssey Therapeutics Secures $213M Series D Funding to Advance Clinical Portfolio

Odyssey Therapeutics, a Boston-based biotech company, has successfully closed a $213 million Series D funding round, bolstering its financial position and paving the way for advancement of its clinical and preclinical pipelines. This latest investment brings the company's total funding to nearly $700 million since its inception in 2021, highlighting strong investor confidence in Odyssey's drug development programs.

NoahAI News9/10/2025
Ronovo Surgical Secures $67M in Funding, Partners with Johnson & Johnson for Robotic Surgery Expansion

Ronovo Surgical Secures $67M in Funding, Partners with Johnson & Johnson for Robotic Surgery Expansion

Shanghai-based Ronovo Surgical has announced a significant milestone in its journey to revolutionize minimally invasive surgery. The company has successfully raised $67 million in a Series D financing round, led by Johnson & Johnson Innovation's venture capital arm, JJDC. This latest funding brings Ronovo's total capital raised in 2025 to over $100 million, positioning the company for accelerated growth in the competitive surgical robotics market.

NoahAI News9/10/2025
FDA Rejects Ultra-Rare Disease Therapy, Dealing Blow to Saol Therapeutics

FDA Rejects Ultra-Rare Disease Therapy, Dealing Blow to Saol Therapeutics

The U.S. Food and Drug Administration (FDA) has rejected Saol Therapeutics' application for SL1009, a potential treatment for pyruvate dehydrogenase complex deficiency (PDCD), an ultra-rare mitochondrial disease affecting children. This decision marks a significant setback in the development of therapies for rare pediatric conditions and highlights the challenges faced by pharmaceutical companies in navigating the regulatory landscape for ultra-rare diseases.

NoahAI News9/9/2025
Lundbeck Announces Major Restructuring, Exits 27 Markets and Lays Off 602 Employees

Lundbeck Announces Major Restructuring, Exits 27 Markets and Lays Off 602 Employees

Danish pharmaceutical company Lundbeck has unveiled a significant restructuring plan, marking a substantial shift in its global operations. The move, part of the company's capital reallocation initiative, will see Lundbeck exit 27 markets and transition to a partnership model, resulting in the layoff of 602 employees.

NoahAI News9/9/2025
Regeneron and Sandoz Reach Settlement on Eylea Biosimilar, Shaping Future of Eye Disease Treatment Market

Regeneron and Sandoz Reach Settlement on Eylea Biosimilar, Shaping Future of Eye Disease Treatment Market

Regeneron Pharmaceuticals and Sandoz have reached a settlement agreement that resolves all patent litigation related to Sandoz's biosimilar version of the eye disease drug Eylea. The agreement allows Sandoz to launch its biosimilar, Enzeevu, in the fourth quarter of 2026 or potentially earlier under certain circumstances. This development marks a significant milestone in the ongoing competition within the ophthalmology market.

NoahAI News9/9/2025
«1...636465...67»